Sotagliflozin, sold under the brand name Zynquista, is a drug for type 1 diabetes.
Routes of administration-By mouth
The most common side effect is genital infection in women.
Other common side effects include diabetic ketoacidosis, diarrhea and genital infection in men.
Sotagliflozin is a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor and is in the class of drugs known as gliflozins.
In patients with type 2 diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events.